UNSPSC 51412004: Cilostazol

This classification denotes a phosphodiesterase inhibitor and antiplatelet agent with the molecular formula C20H27N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N7Z035406B, chemically known as 3,4-dihydro-6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-2(1h)-quinolinone but generally known as cilostazol, which bears US NIH Compound Identifier 2754. European Medicines Agency schedules Cilostazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06273MIG.

UNSPSC 51412004 Cilostazol (Commodity) describes a specific antiplatelet medication, but the recent state and local solicitations tagged under this code do not reflect procurement for cilostazol itself — instead they capture broader pharmaceutical procurement activity spanning advanced life support medications, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. State and local governments use codes in this family to solicit medications for emergency medical services, pharmacy benefit programs, and health agency distribution networks. Issuing bodies include city fire-rescue departments (Tampa Fire Rescue via the City of Tampa Purchasing Department), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP, administered by the Minnesota Department of Administration). The scope of actual procurement spans sealed-bid purchases of specific medication line items with strict expiration and delivery requirements; cooperative purchasing RFPs for generic pharmaceuticals and OTC products distributed through authorized wholesalers; and exploratory RFIs seeking vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels.

Geographic activity centers on Texas, Minnesota (with participation from Oregon and other MMCAP member states), and Florida. Recent opportunities include the City of Tampa's sealed-bid solicitation (Bid No. 26P00188) for advanced life support medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000, seeking four medication line items for Tampa Fire Rescue with nine-month minimum expiration and ten-day delivery timelines; the Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and awards effective July 1, 2026, structured around three authorized wholesalers and weighted 75 percent on price competitiveness; and the Texas HHS Commission's RFI (HHS0017013) posted April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor direct-contracting capacity. The Tampa solicitation includes a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount capped at $10,000.